Atlas Trials

Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma

Clinical trial NCT05833893 · RECRUITING

Trial details

NCT number
NCT05833893
Sponsor
Chinese PLA General Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
nk/T-cell LymphomaNewly DiagnosedAdvanced Lymphoma
Start date
2023-05-01
Primary completion
2025-12-31
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.